Gastroenterology

Predictive Scores Can Help Identify IBD Patients At Risk for Cytomegalovirus

September 25, 2020

Testing all IBD patients for CMV can lead to a concerning overconsumption of resources as well as a delay in treatment.

Man Fung Yuen, MD, PhD: The Future of Hepatitis B Treatment

September 25, 2020

Dr. Yuen discusses some new treatments in the pipeline and how personalized medicine could make an impact in HBV treatment.

C. Diff Vaccine Candidate Fails in Clinical Trial

September 24, 2020

The trial was called off because of futility of the toxoid vaccine candidate.

Infliximab Effective Improving Biomarkers for Pediatric Crohn's Disease

September 23, 2020

The cut points for LCT and nCD64 in Crohn’s disease were not previously known.

Positive Effects of Fecal Material Transplantation for IBD Management

September 23, 2020

Fecal material transplantation for the management of patients with IBD demonstrates a response rate of 53.8% with a complete remission of 37%.

Understanding Current and Future Treatments for Liver Disease

September 20, 2020

This article is the third in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.

Ustekinumab Associated with Increased Risk of Serious Cardiovascular Events

September 18, 2020

Ustekinumab should be prescribed cautiously to those at high cardiovascular risk.

Lower Levels of Continuity of Care Linked to Worse IBD Outcomes for Veterans

September 16, 2020

Low levels of COC associated with a higher likelihood of outpatient flares that required corticosteroids, hospitalizations, and surgical interventions.

FDA Grants Dupilumab Breakthrough Therapy Designation for Eosinophilic Esophagitis

September 14, 2020

There are currently no FDA-approved treatments for eosinophilic esophagitis.

Non-Invasive Test to Detect and Monitor for Liver Disease Among Veterans Signals Clinical Trend for All Americans

September 13, 2020

This article is the second in a series of four articles exploring the epidemic of liver disease called nonalcoholic fatty liver disease and its more severe form, nonalcoholic steatohepatitis.